

**Zoono Group Limited (ASX: ZNO)
ASX ANNOUNCEMENT**

23 October 2026

Cleansing Notice

Under Section 708AA(2)(f) of the Corporations Act 2001

Zoono Group Limited (**Company**) gives this notice under section 708AA(2)(f) of the Corporations Act 2001 (Cth) (**Corporations Act**) as notionally modified by ASIC Corporations (Non-Traditional Rights Issues) Instrument 2026/98 (**AI 2026/98**). References in this notice to the Corporations Act are references to the Corporations Act as modified or amended by AI 2026/98.

The Company has announced it is undertaking an equity raising of up to approximately \$1,609,226 (before costs) via a non-renounceable Rights Issue. The raising comprises a non-renounceable pro-rata entitlement offer of fully paid ordinary shares (**Shares**) on the basis of one (1) new Share for every ten (10) Shares held as at 7:00pm (AEDT) on Thursday, 29 October 2026 to eligible shareholders with a registered address in Australia, New Zealand, Germany, Hong Kong, Singapore and the United Kingdom (Offer or Entitlement Offer).

For further information about the Offer, please refer to the Company's offer document for the Offer pursuant to section 708AA of the Corporations Act dated 23 October 2026 and released on the ASX announcement platform.

Based on the current capital structure (and assuming no options to acquire Shares (**Options**) are exercised prior to the Record Date) a total of an additional 41,262,202 Shares will be issued if the Offer is fully subscribed and the amount raised will be approximately \$1,609,226 (before costs).

As at the date of the Offer Document, the Company has 10,000,000 Options on issue all of which may be exercised prior to the Record Date in order to participate in the Offer.

Any shortfall under the Entitlement Offer will be dealt with by the Company at its discretion as set out in the Offer Document.

The Company hereby confirms that in respect of the Entitlement Offer (as per the requirements of paragraph 708AA(2)(f) of the Corporations Act):

- (a) the Company will offer the Shares for issue without disclosure to investors under Part 6D.2 of the Corporations Act;
- (b) the Company is providing this notice under paragraph 2(f) of section 708AA of the Corporations Act;
- (c) as at the date of this notice the Company has complied with:
 - (i) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - (ii) sections 674 and 674A of the Corporations Act;
- (d) as at the date of this notice, there is no excluded information of the type referred to in sections 708AA(8) and 708AA(9) of the Corporations Act; and
- (e) the potential effect that the issue of the new Shares pursuant to the Entitlement Offer will have on the control of the Company, and the consequences of that effect, will depend on a number of factors, including investor demand. If all shareholders subscribe for their

entitlements, then all shareholders will retain their percentage ownership in the Company, and the issue of Shares under the Entitlement Offer is not expected to have any material effect on the control of the Company. The Company's largest shareholder, Mr Paul Hyslop (Group Managing Director) and his associates, currently has voting power of approximately 28.99% and has indicated that he will take up a portion of his entitlement. If no other shareholders take up their entitlements (and no shortfall is placed), Mr Hyslop's voting power could increase to a maximum of approximately 30.99%. Further information on the potential effect of the Offer on control and the consequences of that effect is set out in Section 3.10 of the Offer Document.

This announcement has been authorised and approved for release to ASX by the Board of Zoono Group Limited.

For further information, please contact:

Zoono Group Limited

Paul Hyslop

Group MD

M: +64 21 659 977

E: paul.hyslop@zoono.com

Paul Ravlich

Group CFO

M: +64 21 075 9176

E: paul.ravlich@zoono.com

About Zoono

Zoono Group Limited is a global biotech company that develops, manufactures and distributes a suite of scientifically validated, long-lasting and environmentally friendly antimicrobial solutions. Zoono's mission is to improve health and well-being through innovative, safe, non-toxic and durable germ protection.

Zoono produces sprays, wipes and foams suited for skin care, surface sanitisers, and mould remediation treatments. The products are based on the 'ZOONO molecule', a unique antimicrobial molecule that bonds to any surface and kills pathogens including bacteria, viruses, algae, fungi and mould.

Zoono's products have received numerous regulatory approvals and the Company's technology claims are supported by independent testing conducted in laboratories worldwide. Zoono is headquartered in New Zealand and its products are available globally.

To learn more, please visit: www.zoono.com